Chances and Challenges of Registry-Based Pharmacovigilance in Multiple Sclerosis: Lessons Learnt from the Implementation of the Multicenter REGIMS Registry

The long-term and potential rare side effects of new immunomodulating drugs for the treatment of multiple sclerosis (MS) are often not well known. Spontaneous case report systems of adverse drug effects are a valuable source in pharmacovigilance, but have several limitations. Primary data collection...

Descripción completa

Detalles Bibliográficos
Autores principales: Simbrich, Alexandra, Thibaut, Jasmine, Khil, Laura, Maximov, Stanislav, Wiendl, Heinz, Berger, Klaus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Special Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813707/
https://www.ncbi.nlm.nih.gov/pubmed/33098059
http://dx.doi.org/10.1007/s40264-020-01007-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813707/
https://www.ncbi.nlm.nih.gov/pubmed/33098059
http://dx.doi.org/10.1007/s40264-020-01007-1

Ejemplares similares